BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 12, 2009
View Archived Issues
Me-Too Drugs Not Dead Yet, but No Exceptions on Value
At last month's BioPharm America conference in San Francisco, biotech experts brushed aside the once-popular business model of using drug delivery or reformulation to provide incremental improvements to existing drugs.
Read More
Money Raised Year to Date
Read More
When Biotechs Hit Hard Times, Leases Can Be the Last Straw
Read More
Money Raised By Biotech in 2009
Read More
Week in Review
Read More
Word on the Street
Read More
Week in Washington
Read More
FDA Approvals in September
Read More
Phase I Clinical Trials Update: September 2009
Read More
Phase II Clinical Trials Update: September 2009
Read More
Pivotal/Phase III Clinical Trials Update: September 2009
Read More
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Read More
Non-U.S. Clinical Trials And Regulatory Actions: September 2009
Read More
FDA Submissions, Approvals And Other Actions: September 2009
Read More
Stock Gainers and Losers For The Week
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More